A MERGER THAT MATTERS
February 2, 2021 | www.mindplusmatter.com
Pegasus, Ashfield Digital and Creative and Cambridge Biomarketing relaunch as Mind+Matter ‘First-in-class’ global agency conceived to confront the toughest challenges in healthcare and wellness New global agency offers 24/7 access to sector experts with ‘unparalleled breadth and depth’ of capabilities The launch of Mind+Matter is one the transformational initiatives being announced as part of the rebranding of parent company Ashfield Healthcare Communications to Ashfield Health
Pegasus – the fifth largest healthcare agency in the UK – has merged with fellow Ashfield Health agencies Ashfield Digital and Creative (ADC) and Cambridge Biomarketing to form Mind+Matter, a ‘global creative powerhouse in health’.
Global President Ben Beckley says Mind+Matter will be the first global agency to create meaningful experiences by bringing data and emotion together to drive behaviour change.
“Health is the most vital, exhilarating frontier in communications, and we had to bring this global team of world-class experts together – even if we’re apart.”
“Covid has shown in an instant how our individual health is also a truly global issue, and we need to offer clients a deeply interconnected, cross-sector response to their challenges – we will supercharge health communications with big thinking that’s unafraid to confront the toughest problems out there.”
The Mind+Matter team now comprises more than 250 people providing global client support. Ben Beckley, former president of Cambridge Biomarketing, leads the new agency from Boston in the US, along with Managing Directors Corrina Safeio, Alyse Sukalski and Carina Whitridge, who head up the UK, US West Coast and US East Coast hubs respectively.
Combining proprietary data, a proven behaviour change methodology and emotive, award-winning creative, the new agency gives clients including Bayer, Holland & Barrett, Novo Nordisk and Sanofi access to a broad range of deep specialisms under one roof to ultimately drive better outcomes for clients and their audiences.
“This is a merger that matters,” explains Ben. “It’s a genuine meeting of minds between three thriving agencies to help our clients realise their biggest ambitions.”
“There has been zero downsizing; instead, we’ve grown to bring together the depth, breadth and mind-blowing talent to compete at the very top of the agency big leagues – and that’s where we’re going.”
At the heart of the offer is the CHANGE methodology, a behavioural science-led strategic methodology co-created with the internationally recognised Centre for Behaviour Change at University College London (itself an expert voice in the public health response to Covid).
With new branding and the formal announcements made, the coming months will see Mind+Matter deliver on an ambitious international growth strategy that will place a proprietary data model alongside this proven behaviour change methodology.
UK Managing Director Corrina Safeio is passionate about taking the CHANGE methodology to the world stage: “We’ve been using this approach for around five years, and on some of our most decorated and effective campaigns,” she explains.
“Now, we can reach more clients and ultimately more people who stand to benefit from evidenced, considered behaviour change.”
The regional MDs are joined on the global leadership team by Annemarie Crivelli as global Head of Experience and Alisa Shakarian as global Creative Director.
Annemarie, who is overseeing a major investment in Mind+Matter’s data capability explains, “Smart, effective omnichannel experiences always start with the data. We’re already aggregating data and applying descriptive analytics to predict behaviour before it happens … but this is really just the start. Watch this space for exciting updates on our capability to push the boundaries of insight, expertise and more experience across disciplines, markets and therapeutic areas.”
Mind+Matter’s bold creative offer will also have the weight of the Ashfield Health network behind it. Ashfield Health is the new brand for Ashfield Healthcare Communications which has been transformed following the appointment of former McCann Health President of the Americas, Amar Urhekar.
“Ashfield Health is now designed to respond better and quicker to the new challenges our clients face. We encourage independence and entrepreneurialism in our specialist agency teams but also have the unique ability to work as one team when needed. By unifying around our common purpose of make it matter, we have stronger connections that enable us to scale rapidly and provide our clients with tailored expert teams. We can truly deliver life-changing work that matters,” said Amar.
Ben says feedback from existing clients has been overwhelmingly positive: “Our clients have already seen what we can do as separate agencies – the outcomes and the awards speak for themselves – and now we can give them even more as a global agency.
“I’m already extremely proud of this team, and we’ve just scratched the surface of what we can achieve together.”
This content was provided by Inizio
Company Details
Latest Content from Inizio
Inizio Engage CEO Jim Sage featured in pharmaphorum’s “12 Questions” series
Discover Jim Sage’s insights on leadership, industry challenges, and the transformative impact of data, technology, and patient-centric innovation in his latest pharmaphorum “12 Questions” interview.
Reframing the Obesity Conversation: Key Takeaways from ObesityWeek® 2025
As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector collaboration driving innovation. At ObesityWeek® 2025 in Atlanta, experts from across Inizio reflected...
How DataGateway unified oncology data for real-world insights & market intelligence
Discover how our DataGateway platform unifies fragmented real-world oncology data into a single, validated dataset that delivers deeper insights and faster decision-making.
Inizio launches InConcert™ to transform pre-launch planning through connected intelligence.
Inizio today announced the launch of InConcert™, a new AI-powered data solution designed to accelerate smarter, evidence-led decisions during the critical pre-launch phase of the product lifecycle.
ESMO 2025 highlights: How storytelling, design & emotion are transforming scientific engagement
Discover key insights from ESMO 2025 on how design, emotion, and sustainability are reshaping medical congress experiences. Featuring expert takes from Inizio leaders.
Preparing for ASH 2025: Pharma’s role in hematology innovation
As the global hematology community prepares for the 67th ASH® Annual Meeting and Exposition, Inizio experts share their perspectives on what’s driving the field forward – and how pharma companies...
AI without limits: A smarter, integrated approach to Medical Affairs
At Inizio Medical, we believe AI isn’t replacing Medical Affairs — it’s redefining what’s possible. Our platform, iON.AI™, enhances human expertise, streamlines complex workflows, and strengthens strategic impact through seamless...
What to expect from Obesity Week 2025: Key trends shaping the future of obesity care
Discover how Inizio experts are shaping the future of obesity care—where science, strategy, and innovation unite to advance cardiometabolic health and drive real-world impact.
AI with intent: How Inizio is redefining pharma through precision and partnership
At Fierce Pharma Week, Inizio revealed how the fusion of human expertise and purposeful AI is reshaping pharma communications and driving real-world impact—discover how this human-centered innovation is defining the...
Leading the future of Intelligent Commercialization™: Where proprietary data, tech, and AI meet expert insight
Inizio is leading the way in Intelligent Commercialization™ by uniting proprietary AI-powered platforms, deep scientific expertise, and proven governance to unlock measurable, lasting value at every stage of commercialization.